zur Hauptseite von Omega-3.ch
Français Italiano
Omega-3
Das kleine ABC über Omega-3
Soviel Omega-3 benötigen Sie
Referenzwerte für Omega-3
Dosierung in Therapie und Heilung
Übersicht der Studienrecherche

Studien über Omega-3 im englischen Originaltext:
Alzheimer
Arteriosklerose
Arthritis
Augen
Blutfett, Cholesterol, Hypertonie
Colitis ulcerosa, Darmerkrankung

Depression
Diabetes mellitus
Hautkrankheiten, Neurodermitis, Psoriasis
Herzbypass
Herzinfarkt
Kinder Hyperaktivität
Kleinkinder Gehirn- /
Sehleistung
Kleinkinder Schlafverhalten
Menstruationsschmerz
Migräne
Morbus Crohn
MS Multiple Sklerose
PTCA Restenosierung
Rheuma
Tumorentstehung: Speiseröhrenkrebs, Brustkrebs, Dickdarmkrebs

Kompendium Omega-3: 6/2001
Omega-3
Omega-6
Arachidonsäure = Omega-6
Versorgung mit Omega-3
Empfehlung für Omega-3
Therapeutische Menge
Wirkung von Omega-3
Häufig gestellte Fragen
Toxizität
Fleischesser
Vegetarier
Kinder
Lebertran
Test: 9 Produkte im Vergleich
Info zum Thema Übersäuerung:
Säuren-Basen Haushalt
Übersäuerung
Test: 14 Basendrinks im Vergleich
Aufbau des Tests
Mineralgehalt
Bioverfügbarkeit
Geschmack
Gebrauchsanweisung
Deklaration
Testresultate
E-Nummer
Nebenwirkungen der
Lebensmittel-Zusatzstoffe
Aminosäuren
5HTP-Tryptophan
Melatonin
DACH-Referenzwerte
empfohlene Werte für Omega-3
empfohlene Werte für Vitamine
geschätzte Werte für Vitamine
Proteine
Glykämischer Index
Die blutzuckersteigernde Wirkung verschiedener Kohlenhydrate
Blutgruppendiät
Links
ImpressumKontak per Mail

Übersäuerung

E-Nummer

Aminosäuren

DACH-Referenzwerte

Omega-3: Fakten - Therapie und Dosierung

Schlafverhalten von Kleinkinder: 2,0g/Tag DHA & EPA spätestens ab 4. Monat der Schwangerschaft.
In Fachzeitschriften wurden folgende Artikel über Omega-3 publiziert. Die Liste dieser Publikationen wurde im April 2003 kompiliert und erhebt keinen Anspruch auf Vollständigkeit. Quelle: MEDLINE.
Die Daten dienen als Referenz für Ärzte und Therapeuten, damit ein mögliches Gesundheitsrisiko für Kleinkinder vermindert werden kann.

Higher maternal plasma docosahexaenoic acid during pregnancy is associated with more mature neonatal sleep-state patterning.
Cheruku SR: Department of Nutritional Sciences, the University of Connecticut, Storrs, USA; Montgomery-Downs HE, Farkas SL, Thoman EB, Lammi-Keefe CJ
Am J Clin Nutr 2002 Sep 76:608-13

Abstract
BACKGROUND: The effect of docosahexaenoic acid (DHA) on the developing fetal central nervous system (CNS) and related functional outcomes in infancy remain unexplored. Sleep and wake states of newborns provide a tool for assessing the functional integrity of the CNS. OBJECTIVE: We investigated whether CNS integrity in newborns, measured with sleep recordings, was associated with maternal concentrations of long-chain polyunsaturated fatty acids, especially DHA. DESIGN: Plasma phospholipid fatty acid concentrations were measured in 17 women at parturition. On postpartum day 1 (P1) and day 2 (P2), a pressure-sensitive pad under the infants' bedding recorded body movements and respiratory patterns to measure sleep and wake states. RESULTS: Maternal plasma phospholipid DHA ranged from 1.91% to 4.5% by wt of total fatty acids. On the basis of previously published data and the median DHA concentration, the women were divided into 2 groups: high DHA (> 3.0% by wt of total fatty acids) and low DHA (</= 3.0% by wt of total fatty acids). Infants of high-DHA mothers had a significantly lower ratio of active sleep (AS) to quiet sleep (QS) and less AS than did infants of low-DHA mothers. Furthermore, the former infants had less sleep-wake transition and more wakefulness on P2. Correlations of maternal DHA status with infant sleep states were consistent with these data. Also, the ratio of maternal n-6 to n-3 fatty acids on P1 was inversely associated with QS and positively associated with arousals in QS. On P2, maternal n-6:n-3 was positively associated with AS, sleep-wake transition, and AS:QS. CONCLUSION: The sleep patterns of infants born to mothers with higher plasma phospholipid DHA suggest greater CNS maturity.
Role of essential fatty acids in the function of the developing nervous system.
Uauy R: Institute of Nutrition and Food Technology (INTA), University of Chile, Santiago, Chile; Peirano P, Hoffman D, Mena P, Birch D, Birch E
Lipids 1996 Mar 31 Suppl:S167-76

Abstract
The basis for n-3 fatty acid essentially in humans includes not only biochemical evidence but functional measures associated with n-3 deficiency in human and nonhuman primates. Functional development of the retina and the occipital cortex are affected by alpha-linolenic acid deficiency and by a lack of docosahexaenoic acid (DHA) in preterm infant formulas and, as reported more recently, in term diets. Functional effects of n-3 supply on sleep-wake cycles and heart rate rhythms support the need for dietary n-3 fatty acids during early development. Our results indicate that n-3 long-chain polyunsaturated fatty acids should be considered provisionally essential for infant nutrition. DHA may also be required by individuals with inherited metabolic defects in elongation and desaturation activity, such as patients with peroxisomal disorders and some forms of retinitis pigmentosa.
nach oben zum Menu